Last reviewed · How we verify

NCT06948071

Enhanced Recovery After Surgery (ERAS) for Complicated Appendicitis

Recruiting now NA Last updated 29 April 2025
What this trial tests

NA trial testing Discharge on oral antibiotics in Appendicitis Acute in 20 participants. Currently enrolling.

Timeline
21 April 2025
Primary endpoint
31 December 2025
28 February 2026

Quick facts

Lead sponsorCedars-Sinai Medical Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date21 April 2025
Primary completion31 December 2025
Estimated completion28 February 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Appendicitis Acute or Appendicitis Perforated. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The exploratory objective of this pilot study is to evaluate the feasibility and safety of an enhanced recovery protocol that will allow adult patients to be discharged to home on an oral antibiotic regimen for three days following a laparoscopic appendectomy for complicated appendicitis. Feasibility will be determined by high compliance and adherence of patients to the postoperative instructions, while safety will be assessed by the incidence of postoperative infectious complications and requirement for re-admission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Appendicitis Acute

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06948071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing